- In February 2026, CorVel Corporation reported past third-quarter and nine-month results to December 31, 2025, showing higher sales of US$235.63 million and US$709.98 million, respectively, alongside increases in net income and earnings per share from continuing operations versus a year earlier.
- CorVel also disclosed that between October 1 and December 31, 2025, it repurchased 185,079 shares for US$13.4 million, bringing total buybacks under its long-running program announced in 1996 to 114,892,649 shares at a cumulative cost of US$886.61 million.
- With recent earnings growth and ongoing share repurchases in focus, we will examine how these developments shape CorVel's broader investment narrative.
AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
What Is CorVel's Investment Narrative?
For CorVel, you really have to buy into a story of disciplined execution in a fairly specialized corner of healthcare, backed by strong profitability and long-standing capital discipline. The latest quarter’s incremental growth in sales and earnings, paired with continued buybacks at lower share prices after a sharp 1-year drawdown, reinforces a management team that keeps returning cash and supporting earnings per share. In the near term, the key catalyst remains whether CorVel can keep expanding its workers’ comp and medical cost containment services without eroding its high margins, especially as competition and pricing pressure remain real possibilities. The fresh earnings beat and additional repurchases do not fundamentally alter those risks, but they sharpen the focus on how sustainable current margins and return on equity truly are.
However, one risk around margin pressure and pricing is easy to underestimate at first glance. CorVel's shares have been on the rise but are still potentially undervalued by 49%. Find out what it's worth.Exploring Other Perspectives
Explore another fair value estimate on CorVel - why the stock might be worth just $95.76!
Build Your Own CorVel Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your CorVel research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free CorVel research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CorVel's overall financial health at a glance.
Contemplating Other Strategies?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
- This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
- Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com